Assessment of specific cell-mediated immunity to SARS-CoV-2: techniques for its measurement Javier Enciso-Benavides, Marlon Garcia-Paita, Santiago Alvarez-Vega, Salyoc Tapia-Rojas, Ana Mayanga-Herrera, Maria J. Pons Revista Del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo, 2025 Comprender la respuesta inmunitaria frente a la infección o vacunación contra SARS-CoV-2 se ha convertido en un objetivo clave para entender la enfermedad, su progresión, y protección frente a futuras infecciones o posibles nuevas variantes que puedan surgir del virus. El objetivo de la presente revisión es destacar la relevancia de la respuesta inmunológica celular y resumir las diferentes metodologías descritas para el estudio de esta respuesta mediada por células T, de memoria, tanto tras la exposición al virus como de la vacunación frente al SARS-CoV-2. Para ello, se incluyen los ensayos de proliferación celular (CFSE, 3H- timidina), métodos de tipificación celular (citometría de flujo), los ensayos inmunológicos basados en la medición de citocinas (ELISA, ELISPOT, Multiplexado en suspensión) y el análisis de genes relacionados con la inmunidad celular mediante técnicas moleculares (RT-qPCR o qPCR y secuenciación).
Highly clonal carbapenem-resistant Acinetobacter baumannii isolates from a Peruvian hospital Maria J. Pons, Fernando Guibert, Jorge Choque-Matos, Luciano A. Palomino-Kobayashi, Paul Fernandez-Castro, Patricia Gonzales, Carmen Valera-Krumdieck, Nidia Vilar, Carla Andrea Alonso, María López, Beatriz Rojo-Bezares, Yolanda Sáenz, Joaquim Ruiz Microbiology Spectrum, 2025 Acinetobacter baumannii is an opportunistic pathogen of great clinical concern, showing high levels of resistance to several antimicrobials, including carbapenems. This study aimed to characterize carbapenem-resistant A. baumannii recovered from a tertiary care hospital (Lima, Peru) in January–February 2021 (during the coronavirus disease 2019 pandemic). Antimicrobial susceptibility was determined by VITEK-2, and the presence of carbapenem-resistance genes by PCR. All 40 A . baumannii isolates were extensively drug-resistant, showing full resistance to all antibiotics tested except ampicillin/sulbactam (95% of resistance) and colistin (10%). The bla OXA-24-like gene was detected in 90% of isolates, and the remaining 10% isolates harbored the bla OXA-23-like gene. Pulsed-field gel electrophoresis classified isolates into three different pulsotypes, grouping 8, 2, and 30 isolates, respectively. Additionally, whole-genome sequencing of two isolates of the main pulsotype revealed that they belonged to ST2 and ST2724 (international clone II) and harbored the bla TEM-1 , bla OXA-66 , bla OXA-72 , and bla ADC-30 β-lactamase genes; mutations in gyrA and parC , aminoglycoside, tetracycline, and sulfonamide resistance genes; and a class 1 integron (In439) containing aac(6′)-Ib′ , catB8 , and aadA1 located inside the AbGRI3 genomic resistance island. These findings highlight the presence of highly resistant and clonally related ST2 of A. baumannii and their relationship with genomes of ST2 of South America. IMPORTANCE Acinetobacter baumannii is a critical pathogen known for causing severe infections in hospitalized patients and for its remarkable ability to develop resistance to multiple antibiotics, including last-line treatments such as carbapenems. In Latin America, data on the genetic background and spread of these resistant strains remain limited. Our study provides a detailed molecular and genomic characterization of extensively drug-resistant A. baumannii isolates collected from a Peruvian hospital during the coronavirus disease 2019 pandemic. We identified a predominant clone belonging to international clone II, which carried multiple resistance genes and a complex resistance island. These findings raise public health concerns, as they highlight the silent spread of high-risk clones in regions with limited surveillance capacity. By contributing valuable local genomic data, our study supports global efforts to track antimicrobial resistance and underscores the urgent need to strengthen molecular monitoring of hospital-associated pathogens also in low- and middle-income countries.
In vitro sulbactam/avibactam synergy against carbapenem-resistant Acinetobacter baumannii from hospitals in Peru Rosario Huerto-Huánuco, Yaneth Quispe-Hualpa, Carla Andrea Alonso, Rosario Oporto-Llerena, Gabriela Soza, Zulema Surichaqui-Cerrón, Carmen Valera-Krumdieck, Luis Castañeda, Maria J Pons, Yolanda Sáenz, Joaquim Ruiz, , Angie K Castillo, Maria Ramos-Chirinos, Jesus Rojas-Jaimes, Delza Tarraga Gonzales, Elsa Nuñez Infanzón, Patricia Gonzales, Luis Pollack, Katherine Alcedo, William Villegas Quispe, Gina Salvador-Luján, Edwin Cuaresma, Nestor Luque, Martín Casapia, Juan C Celis, Alexander Briones, Kovy Arteaga-Livias, María López, Beatriz Rojo-Bezares, Paula Toledano, Andrea C Gomez, Alejandra Zevallos, Joseph Pinto, Kathiuska Z Tutaya, Mignorys V Salcedo Jac Antimicrobial Resistance, 2025 Objectives To evaluate the synergistic activity of ampicillin/sulbactam plus ceftazidime/avibactam in a collection of carbapenem-resistant Acinetobacter baumannii (CR-Ab) from different regions in Peru. Materials and methods One hundred and eighty-four CR-Ab isolates were included in this study. They were identified by amplification of blaOXA-51 and confirmed by MALDI-TOF (matrix-assisted laser desorption ionization time of flight) mass spectrometry and 16S rRNA sequencing. Susceptibility to ampicillin/sulbactam and carbapenems was determined by the disc diffusion method. Synergy was assessed using discs containing ampicillin/sulbactam and ceftazidime/avibactam. The EDTA-disc synergy test was used to screen metallo-β-lactamase-producing isolates, and in isolates showing synergy, the presence of blaNDM was confirmed by PCR. Statistical analysis was performed using Fisher’s exact test. Results High levels of resistance to ampicillin/sulbactam were found in the study. Thus, 1.1% (2/184), 11.4% (21/184) and 87.5% (161/184) of isolates were classified as susceptible, intermediate and resistant to ampicillin/sulbactam, respectively. Synergistic activity was observed in 97.2% of the non-susceptible CR-Ab isolates. The presence of metallo-β-lactamase producers (all blaNDM) was observed in three isolates (1.6%). Conclusions These findings demonstrate high levels of synergistic activity between ampicillin/sulbactam and ceftazidime/avibactam and their potential use as a treatment for CR-Ab.
In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii Barbara Ymaña, Rocío Egoávil-Espejo, Rosario Huerto-Huánuco, Rosario Oporto-Llerena, Carla A. Alonso, Angie K. Castillo, Luciano A. Palomino-Kobayashi, Carmen Valera-Krumdieck, Gabriela Soza, Tamin Ortiz-Gomez, Patricia Gonzales, María López, Gina Salvador-Luján, Beatriz Rojo-Bezares, Martin Casapia, Paula Toledano, Joseph Pinto, Maria Ramos Chirinos, Yolanda Sáenz, Maria J. Pons, Joaquim Ruiz Microbiology Spectrum, 2025 The emergence and spread of third-/fourth-generation cephalosporin and/or carbapenem-resistant Acinetobacter baumannii have become a significant global public health concern, making new treatment alternatives necessary. Thus, the present study aimed to assess in vitro cefiderocol activity against clinical isolates of A. baumannii and analyze their relationship with extended-spectrum β-lactamases (ESBLs) and carbapenemases. Ninety-five A. baumannii clinical isolates were included in the study. Susceptibility to 12 antimicrobial agents was established by automated methods and/or disk diffusion, while that of colistin was determined following microdilution and that of cefiderocol by microdilution using iron-depleted broth. The presence of bla CTX-M , bla PER , bla VEB , bla GES , bla VIM , bla IMP , bla IMI , bla KPC , bla NDM , bla OXA-23G , bla OXA-24G , bla OXA-48G , and bla OXA-58G was established by PCR. The results showed extremely high levels of resistance (>80%) to all the tested antibacterial agents except colistin (11.6%) and cefiderocol (Clinical and Laboratory Standards Institute [CLSI]: 0%; US Food and Drug Administration [FDA]: 1.1%). Following FDA criteria, 22.1% of isolates were intermediate to cefiderocol, with 68.4% of isolates surpassing the European Committee on Antimicrobial Susceptibility Testing epidemiological cut off. Seven colistin-resistant isolates were only susceptible to cefiderocol following CLSI breakpoints, four of them qualifying as cefiderocol-intermediate following FDA breakpoints. No association between the presence of ESBLs or carbapenemases and cefiderocol minimum inhibitory concentration levels was observed. The present results show the potential utility of cefiderocol in the treatment of A. baumannii infections, highlighting the need for judicious use and continuous surveillance to prevent the emergence of cefiderocol-resistant A. baumannii clones. IMPORTANCE Antibiotic resistance is a silent pandemic challenging the treatment of infectious diseases worldwide, but also other medical practices, as, for instance, organ transplantation procedures. In Peru, current levels of antimicrobial resistance are worrisome. In this scenario, we have determined the in vitro activity of cefiderocol against a series of Acinetobacter baumannii exhibiting high levels of resistance to commonly used antibiotics. This activity is independent of the presence of the most common extended-spectrum beta-lactamases or carbapenemases. Obtained results showed the potential of cefiderocol to become an alternative for the treatment of this type of microorganism, but the high number of isolates bordering the considered breakpoint, despite the lack of use of cefiderocol in the country, also shows the need for a prudent use of this antibiotic to maximize its utility while minimizing the selection of resistant isolates.
Antibiotic-Resistant Pseudomonas aeruginosa from Market Meat in Peru Fernando Guibert, Beatriz Rojo-Bezares, Kathya Espinoza, Carla A. Alonso, Rosario Oporto-Llerena, María López, Clara Taboada-Blanco, Yolanda Sáenz, Maria J. Pons, Joaquim Ruiz Foodborne Pathogens and Disease, 2025 Unconsidered microorganisms, such as Pseudomonas aeruginosa, may be often recovered from food samples. This study aimed to characterize seven P. aeruginosa recovered from traditional market chicken meat in Lima, Peru. Antimicrobial susceptibility to 18 antimicrobial agents as well as the presence of amino acid changes in fluoroquinolone targets, 10 mediated colistin resistance ( mcr ) genes and integrons were analyzed. Clonal relationships were determined through pulsed-field gel electrophoresis (PFGE). Serotype by agglutination, multilocus sequence typing and the presence of 14 virulence factors (VFs) were established. Two isolates were multidrug-resistant, all being fluoroquinolone-resistant and exhibited the amino acid changes GyrA T 83 I and ParC S 87 L. No mcr gene was detected in the colistin-resistant isolates. The isolates showed identical PFGE patterns, and the selected P6 isolate belonged to the serotype O:4 and the sequence type 1800, and presented 12 VFs (all but exoU and exlA ). The present study highlights the presence of multidrug and virulent P. aeruginosa in market chicken meat, and suggests cross-contamination during meat manipulation.
Virulence and Resistance of Pseudomonas aeruginosa Isolated from Poultry in Brazil Fernanda Borges Barbosa, Maria J. Pons, Joaquim Ruiz, Yolanda Sáenz, Henrik Christensen, Terezinha Knöbl Microorganisms, 2025 Pseudomonas aeruginosa is an opportunistic pathogen commonly associated with infections in hospitalized and immunocompromised patients due to its virulence and antimicrobial resistance. In the poultry industry, it has been associated with hatchery mortality. This study aimed to characterize P. aeruginosa isolated from pipped eggs, one-day-old chicks, and broiler carcasses obtained from a slaughterhouse in São Paulo state, Brazil. Nineteen strains of P. aeruginosa were selected and their virulence genes were amplified via PCR. Clonality analysis was performed using BOX-PCR, and three strains were selected for whole-genome sequencing (WGS). All isolates carried aprA, plcH, plcN, lasA, lasB, lasI, lasR, rhlAB, and phzH. The exoA gene was detected in 73.7% of strains, while algD was present in 21.1%. The exoY and exoT genes were present in 94.7% of strains (18/19), whereas exoS was present in 47.4% (9/19). None of the isolates harbored the exoU gene. BOX-PCR and phylogenetic analyses revealed diverse clonal patterns. The sequenced strains were classified as O3 ST116, O2 ST1649, and O3 ST1744. The presence of virulence and antimicrobial resistance determinants in poultry-associated strains underscores the need for surveillance, as these isolates may represent a source for transmission of P. aeruginosa to humans. Our findings highlight the importance of monitoring P. aeruginosa within poultry production and emphasize the value of genomic approaches to understand its diversity, evolution, and public health risks.
In vitro ANTIBACTERIAL ACTIVITY OF EXTR ACTS AND PURIFIED FR ACTIONS FROM THE MARINE SPONGE Suberites aff. latus (Demospongiae, Suberitida, Suberitidae) FROM ICA, PERU Erin Villanueva-Coronado, Juan C. Francia-Quiroz, Christian Polo, Oscar Reategui, Báslavi Cóndor-Luján, Aldo G. Indacochea, Maria J. Pons Revista Peruana De Medicina Experimental Y Salud Publica, 2025 Las esponjas marinas constituyen una fuente reconocida de metabolitos con potencial actividad antibacteriana. En el presente estudio se evaluó la actividad antibacteriana de la esponja marina Suberites aff. latus de Ica, Perú. Las muestras de esponja liofilizadas se extrajeron utilizando diclorometano:metanol (1:1), y se fraccionaron mediante extracción en fase sólida en siete fracciones (F1–F7), que iban de la polaridad acuosa a laorgánica. Se determinó la concentración mínima inhibitoria frente a cepas bacterianas Grampositivas/negativas de colección ATCC (American Type Culture Collection). Los resultados mostraron que la mayor actividad fue observada en la fracción F6 del espécimen 01J frente a Klebsiella pneumoniae y Pseudomonas aeruginosa, así como en la fracción F3 del espécimen 02J frente a K. pneumoniae. El análisis químico cualitativo reveló la presencia de alcaloides y saponinas en las muestras. Estos hallazgos ponen de relieve el potencial de Suberites aff. latus de la costa peruana como fuente prometedora de compuestos antibacterianos.
Direct economic costs related to antimicrobial resistance in bloodstream infections isolated from newborns in a perinatal hospital in Peru Maria J Pons, Antonio M Quispe, Miguel Tirado, Gabriela Soza, Joaquim Ruiz International Health, 2025 Background Antimicrobial resistance (AMR) has emerged as a priority for both public health and the global economy. Moreover, information on AMR is scarce, particularly in low/middle-income countries. We evaluated the direct economic cost of microorganisms and AMR. Methods We performed a cross-sectional study to assess the economic costs of neonatal cases diagnosed with bacteremia at the Instituto Nacional Materno Perinatal in Lima, Peru, from January 2017 to June 2018. We used cost invoices calculated by the micro-costing bottom-up approach, as well as the strain identification and antimicrobial susceptibility data, to estimate the direct costs. Results The average costs of bacteremia were US$349 (SD 403) for multidrug-resistant (MDR) strains and US$276 (SD 349) for non-MDR strains. Costs were higher for microorganisms associated with late-onset sepsis (LOS). We found that LOS, multidrug resistance and age were significantly associated with bloodstream infection (BSI) costs. Also, all microorganism groups were associated with increased costs, with the highest average costs for Acinetobacter, followed by Pseudomonas. Conclusions In Peru, BSI costs are strongly associated with AMR. Furthermore, costs increase significantly with LOS, multidrug resistance and the patient's age. We urge health authorities to strengthen measures and strategies against the pressing threat of AMR.
Detection of rare β-lactamase blaSCO-1 from a Klebsiella pneumoniae high-risk clone in Peru Luciano A Palomino-Kobayashi, Rocío Egoávil-Espejo, Gina Salvador-Luján, Pamela Yáñez, Ronnie G Gavilán, Maria J Pons, Joaquim Ruiz Jac Antimicrobial Resistance, 2025 Background The blaSCO-1 gene, which codes for a carbenicillinase, is an uncommon β-lactamase. To the best of our knowledge, we report the first instance of a Klebsiella pneumoniae clinical high-risk isolate carrying blaSCO-1 in Peru. Objectives To characterize a K. pneumoniae clinical isolate carrying blaSCO-1 in Peru, isolated from a tertiary care hospital in Lima, Peru. Methods Susceptibility to amoxicillin/clavulanic acid, amoxicillin/sulbactam, piperacillin/tazobactam, aztreonam, ceftriaxone, cefotaxime, ceftazidime, ceftazidime/avibactam, cefepime, imipenem, meropenem, ciprofloxacin, trimethoprim/sulfamethoxazole, gentamicin, amikacin and tigecycline was determined using the Kirby–Bauer disc diffusion method. Detection of blaSCO-1 was established by Illumina WGS and bioinformatic analyses. All the publicly available genomes from K. pneumoniae carrying blaSCO-1 from the American continent were downloaded from the NCBI Isolates browser for assessment of phylogenetic comparisons. Results The isolate showed resistance to all the tested antibiotics except for ceftazidime/avibactam, carbapenems and tigecycline. Illumina WGS showed the presence of blaSCO-1 and blaOXA-1, blaSHV-28, blaTEM-1, blaCTX-M-15, as well as genes associated with resistance to quinolones, fosfomycin, aminoglycosides, sulphonamides, trimethoprim and phenicols. Moreover, the isolate was ST307, a high-risk clone of K. pneumoniae usually associated with blaCTX-M-15 and/or carbapenemases. Notwithstanding, the latter were not found on this isolate. Phylogenetic relationships were established by comparisons with 19 K. pneumoniae genomes carrying blaSCO-1 from other countries in the Americas, revealing at least three different clades. Conclusions This study highlights the importance of genomic surveillance of uncommon antimicrobial resistance genes such as blaSCO-1, which might contribute to further antimicrobial resistance levels in this country.
In vitro activity of cefiderocol against ESBL-producing and carbapenem-resistant Pseudomonas aeruginosa Rocío Egoávil-Espejo, Barbara Ymaña, Rosario Oporto-Llerena, Dafne Navarro, Rosario Huerto-Huánuco, Gina Salvador-Luján, Tamin Ortiz-Gómez, Maria Pinedo-Bardales, Luciano A Palomino-Kobayashi, Andrea C Gómez, Angie K Castillo, Patricia Gonzales, Carmen Valera-Krumdieck, Gabriela Soza, Cristhian Zapata-Cachay, Maribel Riveros, Maria J Pons, Joaquim Ruiz Jac Antimicrobial Resistance, 2025
blaOXA−51-Negative Acinetobacter calcoaceticus–baumannii Complex as a Cause of Human Infection in Peru Rosario Oporto-Llerena, Rosario Huerto-Huánuco, Yaneth Quispe-Hualpa, Luciano A. Palomino-Kobayashi, Gabriela Soza, Jesús Rojas-Jaimes, Patricia Gonzales, Luis Pollack, Andrea C. Gomez, Gina Salvador-Luján, Edwin Cuaresma, Nestor Luque, Martín Casapia, Kovy Arteaga-Livias, Yolanda Sáenz, Maria J. Pons, Joaquim Ruiz Journal of Tropical Medicine, 2025
FIRST DESCRIPTION OF AN INFECTION BY acinetobacter pitti / lactucae SUBCOMPLEX IN PERU Carla Andrea Alonso, Jorge Choque-Matos, Fernando Guibert, Beatriz Rojo-Bezares, María López, Rocio Egoávil-Espejo, Patricia Gonzales, Carmen Valera-Krumdieck, Maria J. Pons, Yolanda Saénz, Joaquim Ruiz Revista Peruana De Medicina Experimental Y Salud Publica, 2023
First report of CrpP prevalence in a South American country Joaquim Ruiz, Karen Ocampo, Gina Salvador-Luján, Yelinda V. Reyes, Andrea C. Gómez, Carmen Valera-Krumdieck, Ariana D. Baca-Cumpa, Gabriela Soza, Joseph A. Pinto, María Ramos-Chirinos, José Lagos, Maribel Riveros, Maria J. Pons New Microbes and New Infections, 2023
Dengue and COVID-19 Co-Circulation in the Peruvian Amazon: A Population-Based Study Maria J. Pons, Ana Mayanga-Herrera, Gabriela M. Ulloa, Barbara Ymaña, Sabrina Medina, Freddy Alava, Carlos Álvarez-Antonio, Graciela Meza-Sánchez, Carlos Calampa, Wilma Casanova, Cristiam Carey, Hugo Rodríguez-Ferrucci, Amy C. Morrison, Antonio M. Quispe American Journal of Tropical Medicine and Hygiene, 2023
Carrion's disease after blood transfusion María J. Pons, Pedro Eduardo Lovato, João Vitor dos Santos Alves da Silva, Numan Urteaga, Juana del Valle-Mendoza, et al. Blood Transfusion, 2016
FOCUS 1: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia T. M. File, D. E. Low, P. B. Eckburg, G. H. Talbot, H. D. Friedland, J. Lee, L. Llorens, I. A. Critchley, D. A. Thye, on behalf of the FOCUS 1 investigators, J. Pullman, P. Giordano, J. Welker, P. Manos, P. Mehra, T. File, J. De Santo, B. Venkateswaralu, C. Gerald Schrock, W. Tillis, J. A. Winetz, J. M. Gonzalez, A. Ramage, D. D. Eisenhower, C. Koegelenberg, I. Engelbrecht, J. Jurgens, I. Mitha, J. Breedt, M. Gani, J. Roos, M. Basson, L. Van Zyl, R. Meeding, M. Fulat, M. Le Roux, P. E. Bonvehi, M. C. Ganaha, A. L. Gurini, G. Daniel Lopardo, L. Cristina, S. Edwardo Prieto, C. G. Rodiguez, R. Augusto Teijeiro, E. Carmen Pallone, D. H. Pryluka, C. A. da Cunha, N. B. da Silva, A. T. de Faria Freire, C. E. Ferreira Starling, J. Costa Fiterman, F. Gongora Rubio, L. Carlos Losso, M. Patelli, J. Souza Lima, P. J. Zimermann Teixeira, M. A. Carmo Moreira, J. C. Abreu de Oliveira, V. Roudas, E. A. Gamal, I. Leschenko, V. A. Rudnov, A. G. Yevdokimova, A. L. Vertkin, Y. M. Ambalov, I. V. Dvoryashina, E. Zilber, R. F. Khamitov, A. N. Galustyan, O. V. Reshetko, V. A. Senior, M. F. Grosan, G. Jimborean, M. Lupse, G. Aron, D. Olteanu, M. Puschita, C. Gavris, V. M. Tudorache, V. Youroukova, M. Petkova, E. Troshanova, M. Dzhabalyan, G. Kavtaradze, M. Makhviladze, R. Tabukashvili, M. Pons, J. Garbino, D. Genne, M. Rothen, J. O. de Saracho, A. Capelastegui, R. Menendez, A. Torres, C. Shum, V. Falco, E. Bouza, J.-P. Bru, B. Misset, B. Megarbane, J. P. Sollet, J.-M. Molina, K. Dalhoff, J. Lorenz, W. Petermann, G. Rohde, C. Schumann, S. Tasci, J. Zerbst, W. Auch-Schwelk, N. Suttorp, R. Henrich, A. Fertl, C. Grohe, C. Jakobeit, K.-M. Deppermann, H. Batura-Gabryel, D. Pupek-Musialik, P. Piotrowicz, C. Marcisz, K. Czarnobilski, R. Jankowska, K. Janik, M. Gutowska-Jablonska, M. Hamankiewicz, J. Kus, A. Rydzewski, J. Dulawa, E. Ziolko, E. Baranska, M. Wendland, E. Trebas-Pietras, I. Tyszkiewic, J. Bonelli, Z. Baliko, M. Bisits, G. Losonczy, Z. Mark, I. Albert, E. Francovszky, K. Fonay, T. Tetiana Pertseva, V. Yefimov, V. Havrysyuk, V. Melnyk, L. Yashyna, N. Monogarova, Y. Kolchyn, R. Dutka, O. Smolyanyi, N. Tryshchuk, I. Kaydashev, V. Rodionova, V. Neyko, I. Chopey, B. Alekniene, G. Kramilius, S. Naudziunas, S. Miliauskas, V. Nausediene, A. Valavicius, M. Mitic-Milikic, D. Celeketic, Z. Lazic, N. Milinic, T. Pejcic, K. Sukles, M. Jaanus, S. Meriste, D. H. A. Ahmad Mahayiddin, A. P. Bin Abdul Muttalif, K. Kuang Kiat, R. Binte, A. Manap, N. A. bt Md Tarekh, T. Anekthananon, P. Mootsikapun, P. Intalapaporn, C. Pothirat, P. Horsin, C. Churchottaworn, A. Wattanathum, A. Dukat, J. Plutinsky Journal of Antimicrobial Chemotherapy, 2011
Antibiotic Resistance and Virulence Genes in Escherichia coli from Wild Birds in a Peruvian Wetland: K. Espinoza et al. K Espinoza, X Caffo, J Hernández, LA Palomino-Kobayashi, J Ruiz, ... EcoHealth, 1-12 , 2026 2026
Actividad antibacteriana in vitro de extractos y fracciones purificadas de la esponja marina Suberites aff. Latus (Demospongiae, Suberitida, Suberitidae) de Ica, Perú E Villanueva-Coronado, JC Francia-Quiroz, C Polo, O Reategui, ... Revista Peruana de Medicina Experimental y Salud Pública 42, 424-429 , 2026 2026
In vitro antibacterial activity of extracts and purified fractions from the marine sponge Suberites aff. latus (Demospongiae, Suberitida, Suberitidae) from Ica, Peru E Villanueva-Coronado, JC Francia-Quiroz, C Polo, O Reategui, ... Revista Peruana de Medicina Experimental y Salud Pública 42, 424-429 , 2026 2026
Highly clonal carbapenem-resistant Acinetobacter baumannii isolates from a Peruvian hospital MJ Pons, F Guibert, J Choque-Matos, LA Palomino-Kobayashi, ... Microbiology Spectrum 13 (12), e02119-25 , 2025 2025 Citations: 1
In vitro sulbactam/avibactam synergy against carbapenem-resistant Acinetobacter baumannii from hospitals in Peru R Huerto-Huánuco, Y Quispe-Hualpa, CA Alonso, R Oporto-Llerena, ... JAC-Antimicrobial Resistance 7 (6), dlaf217 , 2025 2025
In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii B Ymaña, R Egoávil-Espejo, R Huerto-Huánuco, R Oporto-Llerena, ... Microbiology Spectrum 13 (11), e00844-25 , 2025 2025 Citations: 1
Antibiotic-Resistant Pseudomonas aeruginosa from Market Meat in Peru F Guibert, B Rojo-Bezares, K Espinoza, CA Alonso, R Oporto-Llerena, ... Foodborne Pathogens and Disease 22 (11), 761-767 , 2025 2025 Citations: 2
Virulence and Resistance of Pseudomonas aeruginosa Isolated from Poultry in Brazil FB Barbosa, MJ Pons, J Ruiz, Y Sáenz, H Christensen, T Knöbl Microorganisms 13 (10), 2402 , 2025 2025
Kinetics of anti-SARS-CoV-2 antibodies and hematological parameters in hospitalized pre-vaccination COVID-19 patients in Peru S Tapia-Rojas, AGM Carrasco, MJ Pons, M Ugarte-Gil, ... PeerJ 13, e19771 , 2025 2025
SARS-CoV-2-specific humoral and cellular immunity assessment in Peruvian vaccinated population: a cross-sectional study MY Garcia-Paitan, S Tapia-Rojas, HSA Vega, J Enciso-Benavides, ... PeerJ 13, e19651 , 2025 2025
Direct economic costs related to antimicrobial resistance in bloodstream infections isolated from newborns in a perinatal hospital in Peru MJ Pons, AM Quispe, M Tirado, G Soza, J Ruiz International Health 17 (4), 566-572 , 2025 2025 Citations: 3
Detection of rare β-lactamase bla SCO-1 from a Klebsiella pneumoniae high-risk clone in Peru LA Palomino-Kobayashi, R Egoávil-Espejo, G Salvador-Luján, P Yáñez, ... JAC-Antimicrobial Resistance 7 (3), dlaf089 , 2025 2025 Citations: 2
In vitro activity of cefiderocol against ESBL-producing and carbapenem-resistant Pseudomonas aeruginosa R Egoávil-Espejo, B Ymaña, R Oporto-Llerena, D Navarro, ... JAC-Antimicrobial Resistance 7 (3), dlaf082 , 2025 2025
Carbapenem-Resistant Pseudomonas aeruginosa from Guanay Cormorants on Is. Pescadores, Peru: L. A. Palomino-Kobayashi et al. LA Palomino-Kobayashi, C Zavalaga, C Irigoin-Lovera, ... EcoHealth 22 (2), 268-278 , 2025 2025 Citations: 2
Traditional marketed meats as a reservoir of multidrug-resistant Escherichia coli F Guibert, K Espinoza, C Taboada-Blanco, CA Alonso, R Oporto, ... International Microbiology 28 (Suppl 1), 27-43 , 2025 2025 Citations: 12
Evaluación de la inmunidad celular específica frente al SARS-CoV-2: técnicas para su medición J Enciso-Benavides, M Garcia-Paita, S Alvarez-Vega, S Tapia-Rojas, ... Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo 18 (4 … , 2025 2025
bla OXA−51 ‐Negative Acinetobacter calcoaceticus–baumannii Complex as a Cause of Human Infection in Peru R Oporto-Llerena, R Huerto-Huánuco, Y Quispe-Hualpa, ... Journal of Tropical Medicine 2025 (1), 8851906 , 2025 2025
Determinación e interpretación de la sensibilidad a cefiderocol J Ruiz, R Egoávil-Espejo, B Ymaña, R Oporto-Llerena, MJ Pons South Health 1, e008-e008 , 2024 2024 Citations: 2
Resistance to cephalosporins and quinolones in Escherichia coli isolated from irrigation water from the Rímac river in east Lima, Peru M Huamán Iturrizaga, G Salvador-Luján, L Morales, J Alba Luna, ... Revista Peruana de Medicina Experimental y Salud Pública 41, 114-120 , 2024 2024 Citations: 4
Resistance to cephalosporins and quinolones by Escherichia coli isolated from irrigation water from eastern Lima, Perú M Huamán Iturrizaga, G Salvador-Luján, L Morales, J Alba Luna, ... Instituto Nacional de Salud , 2024 2024
MOST CITED SCHOLAR PUBLICATIONS
Macrolide resistance mechanisms in Enterobacteriaceae : Focus on azithromycin C Gomes, S Martínez-Puchol, N Palma, G Horna, L Ruiz-Roldán, MJ Pons, ... Critical reviews in microbiology 43 (1), 1-30 , 2017 2017 Citations: 187
Transferable mechanisms of quinolone resistance J Ruiz, MJ Pons, C Gomes International journal of antimicrobial agents 40 (3), 196-203 , 2012 2012 Citations: 167
Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru S Levy-Blitchtein, I Roca, S Plasencia-Rebata, W Vicente-Taboada, ... Emerging microbes & infections 7 (1), 1-9 , 2018 2018 Citations: 145
Antimicrobial Susceptibility and Mechanisms of Resistance in Shigella and Salmonella Isolates from Children under Five Years of Age with Diarrhea in Rural … I Mandomando, D Jaintilal, MJ Pons, X Valles, M Espasa, L Mensa, ... Antimicrobial agents and chemotherapy 53 (6), 2450-2454 , 2009 2009 Citations: 125
Presencia de Enterobacteriaceae y Escherichia coli multirresistente a antimicrobianos en carne adquirida en mercados tradicionales en Lima L Ruiz-Roldán, S Martínez-Puchol, C Gomes, N Palma, M Riveros, ... Revista Peruana de Medicina Experimental y Salud Publica 35, 425-432 , 2018 2018 Citations: 80
Resistance to quinolones, cephalosporins and macrolides in Escherichia coli causing bacteraemia in Peruvian children N Palma, MJ Pons, C Gomes, J Mateu, M Riveros, W García, J Jacobs, ... Journal of global antimicrobial resistance 11, 28-33 , 2017 2017 Citations: 79
Validation of a universal set of primers to study animal‐associated microeukaryotic communities J Del Campo, MJ Pons, M Herranz, KC Wakeman, J Del Valle, ... Environmental microbiology 21 (10), 3855-3861 , 2019 2019 Citations: 65
Analysis of quinolone-resistance in commensal and diarrheagenic Escherichia coli isolates from infants in Lima, Peru MJ Pons, S Mosquito, C Gomes, LJ Del Valle, TJ Ochoa, J Ruiz Transactions of the Royal Society of Tropical Medicine and Hygiene 108 (1 … , 2014 2014 Citations: 65
Diarrheagenic Escherichia coli Phylogroups Are Associated with Antibiotic Resistance and Duration of Diarrheal Episode S Mosquito, MJ Pons, M Riveros, J Ruiz, TJ Ochoa The Scientific World Journal 2015 (1), 610403 , 2015 2015 Citations: 63
Antimicrobial resistance in Shigella spp. causing traveller's diarrhoea (1995–2010): a retrospective analysis MJ Pons, C Gomes, S Martinez-Puchol, L Ruiz, L Mensa, J Vila, J Gascón, ... Travel Medicine and Infectious Disease 11 (5), 315-319 , 2013 2013 Citations: 61
Diagnosis of Carrion’s disease by direct blood PCR in thin blood smear negative samples J del Valle Mendoza, W Silva Caso, C Tinco Valdez, MJ Pons, ... PLoS One 9 (3), e92283 , 2014 2014 Citations: 57
Epidemiology and molecular characterization of multidrug-resistant Escherichia coli isolates harboring blaCTX-M group 1 extended-spectrum β-lactamases causing bacteremia and … E Guiral, MJ Pons, D Vubil, M Marí-Almirall, B Sigaúque, SM Soto, ... Infection and drug resistance, 927-936 , 2018 2018 Citations: 52
In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea J Ruiz, L Mensa, C O'Callaghan, MJ Pons, A González, J Vila, J Gascón Diagnostic microbiology and infectious disease 59 (4), 473-475 , 2007 2007 Citations: 49
Cytokine profiles associated with worse prognosis in a hospitalized Peruvian COVID-19 cohort MJ Pons, B Ymaña, A Mayanga-Herrera, Y Sáenz, L Alvarez-Erviti, ... Frontiers in immunology 12, 700921 , 2021 2021 Citations: 44
Pathogenic Acinetobacter species including the novel Acinetobacter dijkshoorniae recovered from market meat in Peru M Marí-Almirall, C Cosgaya, MJ Pons, A Nemec, TJ Ochoa, J Ruiz, I Roca, ... International journal of food microbiology 305, 108248 , 2019 2019 Citations: 44
Current trends in epidemiology and antimicrobial resistance in intensive care units MJ Pons, J Ruiz Journal of Emergency and Critical Care Medicine 3 , 2019 2019 Citations: 44
Escherichia coli ST131 clones harbouring AggR and AAF/V fimbriae causing bacteremia in Mozambican children: Emergence of new variant of fimH27 subclone I Mandomando, D Vubil, N Boisen, L Quintó, J Ruiz, B Sigaúque, ... PLOS Neglected Tropical Diseases 14 (5), e0008274 , 2020 2020 Citations: 43
Aetiology, epidemiology and clinical characteristics of acute moderate-to-severe diarrhoea in children under 5 years of age hospitalized in a referral paediatric hospital in … R Benmessaoud, I Jroundi, M Nezha, C Moraleda, H Tligui, M Seffar, ... Journal of medical microbiology 64 (1), 84-92 , 2015 2015 Citations: 43
High prevalence of Bordetella pertussis in children under 5 years old hospitalized with acute respiratory infections in Lima, Peru I Pavic-Espinoza, S Bendezú-Medina, A Herrera-Alzamora, P Weilg, ... BMC infectious diseases 15 (1), 554 , 2015 2015 Citations: 42
β-Lactamases, transferable quinolone resistance determinants, and class 1 integron-mediated antimicrobial resistance in human clinical Salmonella enterica isolates of non … MO Pérez-Moreno, E Pico-Plana, M de Toro, J Grande-Armas, ... International Journal of Medical Microbiology 303 (1), 25-31 , 2013 2013 Citations: 42